Story

Trump Administration Nears Drug Pricing Deals with Biotech Firms for Medicaid, Report Says

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20261 min read
Trump Administration Nears Drug Pricing Deals with Biotech Firms for Medicaid, Report Says
Text size
Background

The Trump administration plans to announce drug-pricing agreements with several midsized biotech companies, according to a Bloomberg report citing people familiar with the matter. The deals would reportedly involve the companies providing discounts on outpatient drugs to state Medicaid programs.

Details of the Agreements

Under the terms being discussed, the participating companies would agree to align the prices that state Medicaid programs pay with the lower prices they charge in certain foreign countries. This model is often referred to as a "most-favored-nations" approach. In exchange for offering these discounts, the drugmakers would receive key incentives:

  • Exemption from pilot programs that would force similar discounts within the Medicare system.
  • Potential relief from tariffs, which has been part of some discussions, according to the sources.

Participation in this new pricing model would be optional for state Medicaid programs.

Market Impact and Unanswered Questions

Sample IUX Markets – In-articleAd

The financial impact of these potential agreements remains uncertain. It is not yet clear how much the deals would save the federal government or the low-income and disabled patients covered by Medicaid. The names of the specific biotech companies involved have also not been disclosed.

Analysts note that Medicaid already receives substantial, legally mandated discounts from pharmaceutical manufacturers, and patients in the program typically have very low out-of-pocket costs for prescriptions. These existing conditions could limit the incremental savings generated by the new voluntary agreements.

White House Acknowledges Negotiations

While declining to confirm a specific announcement, White House spokesman Kush Desai told Bloomberg that "the Trump administration continues to make great progress negotiating additional most-favored-nations deals to cut drug costs for American patients."

Desai added that any specific deals or events should be considered speculation until they are officially announced by the administration, according to the report.

Read next

More on Stocks
Back to latest news

LATEST